$2.10 and more than 9,322 trades have gone off since this post. More than 3.4 million in volume and climbing.
Inspira™ Technologies Develops a Non-Invasive Blood Sensor Designed to Alert Real-Time Change in Patients – Potentially Targets $2.5 Billion ABG Market
HYLA™ blood sensor intends to reduce the need for actual blood samples to be taken from patients
RA’ANANA, Israel, July 6, 2022 /PRNewswire/ — Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the “Company” or “Inspira Technologies”), a groundbreaking respiratory support technology company, revealed the development of the HYLA™ blood sensor. Without the need to take actual blood samples from patients, Inspira’s non-invasive optical blood sensor is being designed to perform real-time and continuous blood monitoring to alert physicians of immediate signs of changes in a patient’s clinical condition. The HYLA blood sensor is targeting the potential $2.5 billion Point of Care testing, ABG (Arterial Blood Gas) analyzer market.